Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
For the conduct of future interventional age-related macular degeneration (AMD) trials, the availability of clinical study endpoints is key. However, no endpoints have been accepted by regulators for evaluation of treatment for intermediate (i) AMD, i.e. the AMD stage at highest risk of developing irreversible geographic atrophy or macular neovascularization. The European MACUSTAR consortium has recruited more than 700 individuals to develop and validate structural, functional and patient-reported endpoints, enabling future iAMD trials based on a prospective observational, multi-centre cohort study. Reliably assessing candidate endpoints in a setting that involves multiple clinical sites across countries comes with a plurality of challenges in the study set-up, quality of data, recruitment of participants and study conduct. Therefore, the MACUSTAR consortium has established a framework that successfully addresses these topics, provides relevant insights into the natural history of iAMD and its sub-phenotypes, and will open new regulatory pathways. The MACUSTAR study is registered on ClinicalTrials.gov under NCT03349801.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11978948 | PMC |
| http://dx.doi.org/10.1038/s41433-024-03568-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy and safety of therapeutic strategies for EGFRvIII positive recurrent glioblastoma.
iScience
September 2025
Beijing Institute of Brain Disorders, Laboratory of Brain Disorders, Ministry of Science and Technology, Collaborative Innovation Center for Brain Disorders, Capital Medical University, No.10 Xitoutiao You'anmenwai Fengtai District, Beijing 100069, P.R. China.
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, and EGFRvIII mutation has been associated with treatment resistance and poor prognosis, highlighting the need for more effective therapeutic strategies. We conducted a random-effects Bayesian network meta-analysis to compare the efficacy and safety of treatments for EGFRvIII-positive recurrent GBM (rGBM), evaluating overall survival (OS), progression-free survival (PFS), and objective response rate (ORR). Seven clinical trials were included ( = 716).
View Article and Find Full Text PDFA machine learning-based analysis method for small molecule high content screening of three-dimensional cancer spheroid morphology.
Mol Pharmacol
August 2025
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland. Electronic address:
Although multiparameter cellular morphological profiling methods and three-dimensional (3D) biological model systems can potentially provide complex insights for pharmaceutical discovery campaigns, there have been relatively few reports combining these experimental approaches. In this study, we used the U87 glioblastoma cell line grown in a 3D spheroid format to validate a multiparameter cellular morphological profiling screening method. The steps of this approach include 3D spheroid treatment, cell staining, fully automated digital image acquisition, image segmentation, numerical feature extraction, and multiple machine learning approaches for cellular profiling.
View Article and Find Full Text PDFAdded Diagnostic Value of Intravascular Ultrasound Over Venography in "High Risk for Dialysis Circuit Vascular Access Failure" ESRD Patients.
Ann Vasc Surg
September 2025
Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address:
Objectives: As a two-dimensional modality, venography has limitations in its capacity to measure lumen caliber and to assess stenotic disease accurately. This has implications in the management of end-stage renal-disease (ESRD) patients "no-option" candidates access for arteriovenous fistula (AVF) or graft (AVG) creation secondary to high risk of vascular access failure. The incremental diagnostic and clinical impact of intravascular ultrasound (IVUS) was quantified in this tunneled dialysis catheter dependent ESRD cohort.
View Article and Find Full Text PDFComputational approaches for toxicology and Pharmacokinetic properties prediction.
J Pharmacokinet Pharmacodyn
September 2025
Department of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Brazil.
Pharmacokinetics and toxicological studies how the body reacts to a specific administered substance, such as a drug, toxin, or food. Each substance experiences these four steps: absorption, distribution, metabolism, and excretion, which are the main parameters in pharmacokinetics studies. Many toxic endpoints exist.
View Article and Find Full Text PDFThe predictive validity of pontine volume change in spinocerebellar ataxia type 1 (SCA1).
Neurobiol Dis
September 2025
Department of Neurology, Donders Institute for Brain, Cognition, and Behavior, Radboud University Medical Center, the Netherlands. Electronic address:
Background: Pontine volume previously emerged as a sensitive MR marker to track disease progression in SCA1. To accept this marker as a surrogate clinical trial endpoint, long-term follow-up is necessary to confirm its sensitivity to change and to establish its predictive validity.
Objective: (1)Confirm the sensitivity to change in pontine volume after two years and identify predictors of volume reduction, and (2)to evaluate the predictive value of one-year changes in pontine volume on subsequent clinical progression after two years.